New York State Common Retirement Fund Reduces Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

New York State Common Retirement Fund decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 99.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,478 shares of the company's stock after selling 4,552,174 shares during the period. New York State Common Retirement Fund owned approximately 0.06% of Omnicell worth $1,072,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in OMCL. Vanguard Group Inc. lifted its holdings in shares of Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company's stock valued at $231,374,000 after purchasing an additional 674,824 shares in the last quarter. Pacer Advisors Inc. boosted its position in Omnicell by 321,488.8% during the 4th quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company's stock worth $39,814,000 after acquiring an additional 1,057,698 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Omnicell by 3.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 638,646 shares of the company's stock worth $24,032,000 after acquiring an additional 19,601 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Omnicell by 48.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 566,704 shares of the company's stock valued at $21,325,000 after purchasing an additional 184,213 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Omnicell by 12,425.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company's stock valued at $21,731,000 after purchasing an additional 478,636 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on OMCL shares. Benchmark reaffirmed a "buy" rating and issued a $38.00 target price on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company lowered their target price on Omnicell from $28.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $42.20.

Omnicell Stock Performance

Shares of Omnicell stock traded down $0.13 during trading on Friday, hitting $30.12. 537,091 shares of the stock were exchanged, compared to its average volume of 467,758. Omnicell, Inc. has a 1-year low of $25.69 and a 1-year high of $77.14. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -65.48, a price-to-earnings-growth ratio of 136.35 and a beta of 0.77. The company has a fifty day moving average price of $28.06 and a 200-day moving average price of $31.37. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The firm had revenue of $258.85 million for the quarter, compared to the consensus estimate of $256.00 million. As a group, equities analysts predict that Omnicell, Inc. will post 0.16 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.